Indwelling Catheters Market: as the CDC recommends antimicrobial catheters specifically when CAUTI rates fail to decrease following comprehensive infection control strategies, catheter material science shifts from a generic commodity choice into a targeted clinical escalation tool deployed only after standard prevention protocols have been exhausted, so antimicrobial and biofilm-resistant coating technologies capture a defined, protocol-driven second-line market rather than competing for first-line adoption against uncoated devices.

The global indwelling catheters market size was USD 1.92 Billion in 2025 and is expected to register a revenue CAGR of 5.4% during the forecast period. Market revenue growth is driven by factors such as CDC guidance recommending antimicrobial catheters specifically when CAUTI rates fail to decrease following comprehensive infection control strategies, continued clinical evidence supporting silver alloy coating technology in high-risk patient populations, and FDA recognition of a new device classification for Foley catheters with enhanced safety features. The first driving factor is CDC guidance that positions antimicrobial catheters as a targeted, protocol-driven escalation tool rather than a universal first-line replacement for standard catheters. The CDC recommends antimicrobial catheters specifically when catheter-associated urinary tract infection rates fail to decrease following implementation of comprehensive infection control strategies, establishing a defined clinical decision point that drives antimicrobial catheter adoption at facilities that have already exhausted standard prevention protocols. The second driving factor is continued clinical evidence supporting silver alloy coating technology, exemplified by BD’s Bardex I.C. Foley Catheter with Bactiguard silver alloy coating. The Kai-Larsen multicenter study of 1,000 patients demonstrated a 69% CAUTI reduction using the Bactiguard silver alloy coated catheter, which remains suitable for indwelling use for up to 28 days, providing the kind of large-scale clinical evidence base that supports CDC-guided antimicrobial catheter escalation decisions. The third driving factor is FDA recognition of new device classifications and clearance pathways specifically addressing catheter designs with enhanced safety features beyond material coating alone. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a large-scale clinical study establishing an antimicrobial catheter’s CAUTI reduction rate widens its own addressable market as hospital infection control committees cite that specific evidence base when making CDC-guided escalation decisions, letting one well-documented clinical trial drive adoption decisions across many hospitals facing the same CDC guidance threshold rather than each hospital independently generating its own evidence. Once a large multicenter study establishes a specific, quotable CAUTI reduction percentage for a given antimicrobial catheter technology, hospital infection control committees across many facilities can cite that same published evidence when justifying an escalation decision under CDC guidance, so the value of a well-powered clinical study compounds across the addressable hospital market rather than being confined to the study sites themselves. As a result, demand and revenue share are concentrating around antimicrobial catheter technologies with the strongest published, multicenter clinical evidence base, and the forecast tilts toward vendors that can point to specific, large-sample CAUTI reduction data rather than smaller or unpublished evidence. For instance, InnoCare Urologics received FDA 510(k) clearance in December 2024 for its Egress Safety Catheter as the first device cleared under a new FDA classification specifically for Foley catheters with additional safety features, including an auto-deflating balloon designed for high-risk ICU and cognitively impaired patients, illustrating how catheter design innovation is expanding beyond antimicrobial coating into mechanical safety feature differentiation. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is CDC guidance that establishes a specific, protocol-defined clinical trigger point for antimicrobial catheter adoption rather than leaving the decision to general clinical preference. A defined guideline trigger, CAUTI rates failing to decrease following comprehensive infection control strategy implementation, gives hospital infection control committees a clear, defensible basis for escalating to antimicrobial catheters, and this clarity is what sustains steady antimicrobial catheter demand at facilities that have documented standard-protocol CAUTI rates above target, so CDC guidance structure and antimicrobial catheter adoption pattern are directly linked. Hospitals implementing comprehensive CAUTI prevention bundles that nonetheless continue to show elevated infection rates represent the core addressable market for antimicrobial catheter escalation under CDC guidance, distinguishing this market from a catheter category driven by generalised, undifferentiated safety marketing alone. The effect on the market is that antimicrobial catheter demand tracks the population of hospitals with documented, guideline-qualifying CAUTI rate performance rather than the full universe of hospitals using indwelling catheters. These are some of the key factors driving revenue growth of the market.

The second driver is the availability of large-scale, well-powered clinical evidence documenting specific CAUTI reduction rates for antimicrobial catheter technologies. A hospital infection control committee justifying an antimicrobial catheter escalation decision under CDC guidance needs citable, credible evidence of effectiveness, and a multicenter study with a specific, quotable reduction percentage provides exactly the evidence quality that committee to committee decision-making requires, so published clinical study strength and adoption decision confidence are directly linked. The Kai-Larsen multicenter study of 1,000 patients demonstrated a 69% CAUTI reduction using BD’s Bardex I.C. Foley Catheter with Bactiguard silver alloy coating, which remains suitable for indwelling use for up to 28 days, providing a large, specific evidence base that hospital committees across many facilities can reference when evaluating antimicrobial catheter adoption. The effect on the market is that vendors with the strongest published, multicenter clinical evidence capture disproportionate share of the CDC-guideline-driven escalation market relative to vendors offering antimicrobial technology without comparable evidence depth. These are some of the key factors driving revenue growth of the market.

“The Kai-Larsen multicenter study of 1,000 patients documented a 69% CAUTI reduction using BD’s Bardex I.C. Foley Catheter with Bactiguard silver alloy coating, providing the kind of large, specific clinical evidence base that hospital infection control committees cite when justifying antimicrobial catheter escalation decisions under CDC guidance.”

The third driver is FDA regulatory recognition of catheter design innovation focused on mechanical safety features rather than antimicrobial material properties alone. A new FDA device classification specifically for catheters with enhanced safety features, such as an auto-deflating balloon, creates a defined regulatory pathway that other manufacturers can now follow, and this pathway clarity is what enables broader industry investment in mechanical safety innovation beyond the antimicrobial coating approach that has dominated catheter innovation historically, so the new classification and expanding design innovation investment are directly linked. InnoCare Urologics received FDA 510(k) clearance in December 2024 for its Egress Safety Catheter as the first device cleared under this new FDA classification for Foley catheters with additional safety features, including an auto-deflating balloon designed specifically for high-risk ICU and cognitively impaired patients at elevated risk of catheter-related trauma. The effect on the market is that catheter design competition is diversifying beyond antimicrobial coating technology into mechanical safety feature innovation as a distinct product differentiation axis. These are some of the key factors driving revenue growth of the market.

However, the indwelling catheters market faces adoption constraints from the cost premium of antimicrobial and specialty safety-feature catheters relative to standard devices, the CDC’s own guidance limiting antimicrobial catheter use to a defined escalation scenario, and the broader clinical priority CDC guidance places on reducing catheter use and dwell time altogether. Because antimicrobial and silver alloy coated catheters carry a meaningful cost premium over standard uncoated catheters, and because CDC guidance itself recommends their use only when standard infection control strategies have already failed to reduce CAUTI rates below target thresholds, the addressable market for premium catheter technology is structurally capped below the full indwelling catheter installed base by design, meaning even hospitals that could clinically benefit from antimicrobial catheters may not qualify for guideline-supported escalation if their baseline infection control programme has not yet been fully implemented and evaluated. The broader CDC emphasis on reducing indwelling catheter use and duration altogether, rather than solely on catheter material selection, is a second constraint, since CDC guidance prioritises avoiding unnecessary catheterisation, using external devices where clinically appropriate, and minimising dwell time through nurse-driven removal protocols as the primary CAUTI prevention strategy, positioning catheter material technology as a secondary intervention layered on top of, rather than a substitute for, appropriate catheter use reduction, and hospitals successfully reducing overall catheter utilisation may reduce total catheter volume even as antimicrobial share within that smaller volume increases. Reimbursement and procurement cost sensitivity is the third constraint, since hospital purchasing committees weighing antimicrobial catheter cost premiums against CAUTI-related cost avoidance, estimated at meaningful additional cost per infection, must build a facility-specific business case that depends on accurately tracking baseline CAUTI rates and cost data that not every hospital’s infection control and procurement processes support equally well. These factors substantially limit indwelling catheters market growth over the forecast period.

Based on product, the global indwelling catheters market is segmented into Foley (indwelling) catheters, intermittent catheters, and external/condom catheters. Foley catheters hold the largest revenue share, because they remain the standard device for continuous urinary drainage across hospital ICU and general ward settings, which suits the market’s core CDC-guidance-driven antimicrobial escalation dynamic. Intermittent catheters remain established for patients managing urinary retention without continuous indwelling drainage, and they carry a lower CAUTI risk profile given their non-continuous use pattern, but they address a clinically distinct patient population from Foley catheter indications. External/condom catheters are expected to register rapid revenue growth in the global indwelling catheters market over the forecast period, driven by the CDC’s guidance recommending external devices in lieu of indwelling Foleys where clinically appropriate, which is why hospitals reducing overall indwelling catheter utilisation are increasingly adopting external alternatives for eligible male patients.

Based on material, the global indwelling catheters market is segmented into silicone, latex (coated), and antimicrobial/silver alloy coated materials. Silicone holds the largest revenue share, because it remains the standard material choice for most indwelling catheter applications given its biocompatibility and lower allergic reaction risk relative to latex, which suits the majority of standard, non-escalated catheterisation cases. Antimicrobial/silver alloy coated material is expected to register the fastest revenue growth rate in the global indwelling catheters market over the forecast period, driven directly by CDC guideline-triggered escalation adoption and the Kai-Larsen study’s 69% CAUTI reduction evidence, which is why this category represents the fastest-growing material segment despite its smaller current base.

CAUTI prevention/high-risk patients application is expected to account for a significantly large and fastest-growing revenue share in the global indwelling catheters market during the forecast period

Based on application, the global indwelling catheters market is segmented into CAUTI prevention/high-risk patients and standard urinary retention management applications. Standard urinary retention management holds the largest revenue share, reflecting the broad base of routine indwelling catheterisation across hospital and long-term care settings not specifically triggered by CDC CAUTI escalation guidance. CAUTI prevention/high-risk patients is expected to register the fastest revenue growth rate in the global indwelling catheters market over the forecast period, driven directly by CDC guideline-triggered antimicrobial catheter escalation and specialty safety-feature devices such as InnoCare’s Egress Safety Catheter for high-risk ICU and cognitively impaired patients.

Based on regional analysis, the indwelling catheters market in North America accounted for largest revenue share in 2025. The United States leads because it is the jurisdiction where CDC CAUTI prevention guidance directly shapes hospital antimicrobial catheter escalation protocols, and because BD, Coloplast, and InnoCare Urologics concentrate significant commercial and regulatory activity in the country. InnoCare Urologics’ December 2024 FDA clearance for its Egress Safety Catheter launched first into the United States hospital ICU market. The concentration of CDC guideline authority and FDA clearance activity in the United States also means new catheter safety and antimicrobial technology is typically adopted in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national indwelling catheters markets within Europe. Coloplast, headquartered in the region, maintains a strong European installed base, and national health system infection control guidance across much of Europe parallels, though does not identically replicate, CDC guideline structure. The result is steady rather than rapid growth, shaped more by established infection control infrastructure than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and India represent the three largest national indwelling catheters markets within the region. Expanding hospital infection control programme investment and rising CAUTI awareness in China and India are driving new antimicrobial catheter demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national indwelling catheters markets within the region. Hospital infection control programmes in both countries are gradually adopting more structured CAUTI prevention protocols, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised antimicrobial catheters that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial indwelling catheters markets within the GCC. The UAE is the most established indwelling catheters market on the continent given its concentrated private hospital infrastructure, while the wider Gulf states and broader African markets are still building the infection control programme infrastructure that CDC-style guideline-driven antimicrobial catheter escalation depends on.